Skip to main content
SpringerLink
Log in
Book cover

Pituitary Disorders of Childhood pp 121–139Cite as

Gigantism and Acromegaly

  • Chapter
  • First Online:

Part of the book series: Contemporary Endocrinology ((COE))

Abstract

Gigantism and acromegaly are rare clinical entities caused by growth hormone (GH) hypersecretion. Their main difference is the status of the epiphyseal growth plates at the time of the GH hypersecretion; gigantism occurs during childhood when growth plates are not yet fused, and acromegaly occurs after epiphyseal fusion. The most common cause of both gigantism and acromegaly is a benign GH-secreting pituitary tumor (somatotroph tumor) that occurs sporadically. However, both disorders can occur in the setting of known genetic syndromes, including familial isolated pituitary adenoma, X-linked acrogigantism, Carney complex, multiple endocrine neoplasia type 1, McCune-Albright syndrome, paraganglioma, pheochromocytoma and pituitary adenoma association, and neurofibromatosis type 1. Typical clinical features include coarse facial characteristics with frontal bossing and prognathism, excessive sweating, and enlargement of the hands and feet. Clinical manifestations can be broadly categorized into local effects from the pituitary tumor and systemic effects of the GH/IGF1 excess. Measurement of serum IGF-1 is the best screening test for gigantism and acromegaly. Diagnosis is confirmed by failure of suppression of GH to less than 1 μg/L after a standardized oral glucose load. The goal of treatment is to normalize GH secretion and correct clinical symptoms while preserving anterior pituitary function. Surgery is the first line of therapy for patients with a distinct pituitary micro- or macroadenoma. Medical treatment consists of three different classes of medications: somatostatin analogues, dopamine agonists, and growth hormone receptor antagonist. Radiotherapy may be used as an adjuvant therapy when surgery and medical therapy are unsuccessful.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Lodish MB, Trivellin G, Stratakis CA. Pituitary gigantism. Curr Opin Endocrinol Diabetes Obes. 2016;23(1):72–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Pandey P, Ojha BK, Mahapatra AK. Pediatric pituitary adenoma: a series of 42 patients. J Clin Neurosci. 2005;12(2):124–7.

    Article  CAS  PubMed  Google Scholar 

  3. Cannavo S, Venturino M, Curto L, De Menis E, D’Arrigo C, Tita P, et al. Clinical presentation and outcome of pituitary adenomas in teenagers. Clin Endocrinol. 2003;58(4):519–27.

    Article  CAS  Google Scholar 

  4. Ayuk J. Growth hormone and its disorders. Postgrad Med J. 2006;82(963):24–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Brooks AJ, Waters MJ. The growth hormone receptor: mechanism of activation and clinical implications. Nat Rev Endocrinol. 2010;6(9):515–25.

    Article  CAS  PubMed  Google Scholar 

  6. Lanning NJ, Carter-Su C. Recent advances in growth hormone signaling. Rev Endocr Metab Disord. 2007;7(4):225–35.

    Article  CAS  Google Scholar 

  7. Waters MJ, Shang CA, Behncken SN, Tam SP, Li H, Shen B, et al. Growth hormone as a cytokine. Clin Exp Pharmacol Physiol. 1999;26(10):760–4.

    Article  CAS  PubMed  Google Scholar 

  8. Cunningham B, Ultsch M, De Vos A, Mulkerrin M, Clauser K, Wells J. Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule. Science. 1991;254(5033):821–5.

    Article  CAS  PubMed  Google Scholar 

  9. Argetsinger LS, Carter-Su C. Mechanism of signaling by growth hormone receptor. Physiol Rev. 1996;76(4):1089–107.

    Article  CAS  PubMed  Google Scholar 

  10. Le Roith D, Bondy C, Yakar S, Liu J-L, Butler A. The somatomedin hypothesis: 2001. Endocr Rev. 2001;22(1):53–74.

    Article  PubMed  Google Scholar 

  11. Daughaday WH, Hall K, Raben MS, Salmon WD, Leo Van Den Brande J, Van Wyk JJ. Somatomedin: proposed designation for sulphation factor. Nature. 1972;235(5333):107.

    Article  CAS  PubMed  Google Scholar 

  12. Hannah-Shmouni F, Trivellin G, Stratakis CA. Genetics of gigantism and acromegaly. Growth Horm IGF Res. 2016;30–31:37–41.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Eugster E. Gigantism. In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, et al., editors. Endotext. South Dartmouth: MDText.com, Inc.; 2000.

    Google Scholar 

  14. Sotos JF. Overgrowth. Clin Pediatr. 1996;35(11):577–90.

    Article  Google Scholar 

  15. Melmed S. Acromegaly. N Engl J Med. 1990;322(14):966–77.

    Article  CAS  PubMed  Google Scholar 

  16. Felix IA, Horvath E, Kovacs K, Smyth HS, Killinger DW, Vale J. Mammosomatotroph adenoma of the pituitary associated with gigantism and hyperprolactinemia. A morphological study including immunoelectron microscopy. Acta Neuropathol. 1986;71(1–2):76–82.

    Article  CAS  PubMed  Google Scholar 

  17. Dubuis JM, Deal CL, Drews RT, Goodyer CG, Lagacé G, Asa SL, et al. Mammosomatotroph adenoma causing gigantism in an 8-year old boy: a possible pathogenetic mechanism. Clin Endocrinol. 1995;42(5):539–49.

    Article  CAS  Google Scholar 

  18. Zimmerman D. Congenital gigantism due to growth hormone-releasing hormone excess and pituitary hyperplasia with adenomatous transformation. J Clin Endocrinol Metab. 1993;76(1):216–22.

    CAS  PubMed  Google Scholar 

  19. Asa SL, Scheithauer BW, Bilbao JM, Horvath EVA, Ryan N, Kovacs K, et al. A case for hypothalamic acromegaly: a clinicopathological study of six patients with hypothalamic gangliocytomas producing growth hormone-releasing factor*. J Clin Endocrinol Metabol. 1984;58(5):796–803.

    Article  CAS  Google Scholar 

  20. Ghazi AA, Amirbaigloo A, Dezfooli AA, Saadat N, Ghazi S, Pourafkari M, et al. Ectopic acromegaly due to growth hormone releasing hormone. Endocrine. 2012;43(2):293–302.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  21. Vierimaa O. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science. 2006;312(5777):1228–30.

    Article  CAS  PubMed  Google Scholar 

  22. Leontiou CA, Gueorguiev M, van der Spuy J, Quinton R, Lolli F, Hassan S, et al. The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab. 2008;93(6):2390–401.

    Article  CAS  PubMed  Google Scholar 

  23. Trivellin G, Daly AF, Faucz FR, Yuan B, Rostomyan L, Larco DO, et al. Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. N Engl J Med. 2014;371(25):2363–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Daly AF, Lysy PA, Desfilles C, Rostomyan L, Mohamed A, Caberg J-H, et al. GHRH excess and blockade in X-LAG syndrome. Endocr Relat Cancer. 2015;23(3):161–70.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Carney JA, Gordon H, Carpenter PC, Shenoy BV, Go VL. The complex of myxomas, spotty pigmentation, and endocrine overactivity. Medicine. 1985;64(4):270–83.

    Article  CAS  PubMed  Google Scholar 

  26. Stratakis CA. Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. J Clin Endocrinol Metab. 2001;86(9):4041–6.

    Article  CAS  PubMed  Google Scholar 

  27. Beckers A, Lodish MB, Trivellin G, Rostomyan L, Lee M, Faucz FR, et al. X-linked acrogigantism syndrome: clinical profile and therapeutic responses. Endocr Relat Cancer. 2015;22(3):353–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Agarwal S. Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states. Hum Mol Genet. 1997;6(7):1169–75.

    Article  CAS  PubMed  Google Scholar 

  29. Mutch MG, Dilley WG, Sanjurjo F, DeBenedetti MK, Doherty GM, Wells SA, et al. Germline mutations in the multiple endocrine neoplasia type 1 gene: evidence for frequent splicing defects. Hum Mutat. 1999;13(3):175–85.

    Article  CAS  PubMed  Google Scholar 

  30. Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metabol. 2012;97(9):2990–3011.

    Article  CAS  Google Scholar 

  31. Brandi ML. CONSENSUS: guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86(12):5658–71.

    Article  CAS  PubMed  Google Scholar 

  32. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM. Activating mutations of the stimulatory G protein in the McCune–Albright syndrome. N Engl J Med. 1991;325(24):1688–95.

    Article  CAS  PubMed  Google Scholar 

  33. Lumbroso S, Paris F, Sultan C. McCune-Albright syndrome: molecular genetics. J Pediatr Endocrinol Metabol. 2002;15(Suppl 3):875–82.

    CAS  Google Scholar 

  34. Vortmeyer AO, Gläsker S, Mehta GU, Abu-Asab MS, Smith JH, Zhuang Z, et al. SomaticGNASMutation causes widespread and diffuse pituitary disease in acromegalic patients with McCune-Albright syndrome. J Clin Endocrinol Metabol. 2012;97(7):2404–13.

    Article  CAS  Google Scholar 

  35. Akintoye SO, Chebli C, Booher S, Feuillan P, Kushner H, Leroith D, et al. Characterization ofgsp-mediated growth hormone excess in the context of McCune-Albright syndrome. J Clin Endocrinol Metabol. 2002;87(11):5104–12.

    Article  CAS  Google Scholar 

  36. Collins MT, Singer FR, Eugster E. McCune-Albright syndrome and the extraskeletal manifestations of fibrous dysplasia. Orphanet J Rare Dis. 2012;7(Suppl 1):S4.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Xekouki P, Szarek E, Bullova P, Giubellino A, Quezado M, Mastroyannis SA, et al. Pituitary adenoma with Paraganglioma/Pheochromocytoma (3PAs) and succinate dehydrogenase defects in humans and mice. J Clin Endocrinol Metabol. 2015;100(5):E710–E9.

    Article  CAS  Google Scholar 

  38. Costin G, Fefferman RA, Kogut MD. Hypothalamic gigantism. J Pediatr. 1973;83(3):419–25.

    Article  CAS  PubMed  Google Scholar 

  39. Drimmie FM, Maclennan AC, Nicoll JAR, Simpson E, McNeill E, Donaldson MDC. Gigantism due to growth hormone excess in a boy with optic glioma. Clin Endocrinol. 2000;53(4):535–8.

    Article  CAS  Google Scholar 

  40. Josefson J, Listernick R, Fangusaro JR, Charrow J, Habiby R. Growth hormone excess in children with neurofibromatosis type 1-associated and sporadic optic pathway tumors. J Pediatr. 2011;158(3):433–6.

    Article  CAS  PubMed  Google Scholar 

  41. Rostomyan L, Daly AF, Petrossians P, Nachev E, Lila AR, Lecoq AL, et al. Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients. Endocr Relat Cancer. 2015;22(5):745–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Daughaday WH. Pituitary gigantism. Endocrinol Metab Clin N Am. 1992;21(3):633–47.

    Article  CAS  Google Scholar 

  43. Rostomyan L, Daly AF, Beckers A. Pituitary gigantism: causes and clinical characteristics. Ann Endocrinol. 2015;76(6):643–9.

    Article  Google Scholar 

  44. Blumberg D, Sklar C, Bell J, David R. Acromegaly presenting in infancy. Pediatric Res. 1987;21(4):244A.

    Article  Google Scholar 

  45. Gelber SJ, Heffez DS, Donohoue PA. Pituitary gigantism caused by growth hormone excess from infancy. J Pediatr. 1992;120(6):931–4.

    Article  CAS  PubMed  Google Scholar 

  46. Lugo G, Pena L, Cordido F. Clinical manifestations and diagnosis of acromegaly. Int J Endocrinol. 2012;2012:1–10.

    Article  Google Scholar 

  47. Katznelson L, Laws ER, Melmed S, Molitch ME, Murad MH, Utz A, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metabol. 2014;99(11):3933–51.

    Article  CAS  Google Scholar 

  48. Ezzat S, Forster MJ, Berchtold P, Redelmeier DA, Boerlin V, Harris AG. Acromegaly. Medicine. 1994;73(5):233–40.

    Article  CAS  PubMed  Google Scholar 

  49. Vilar L, Vilar CF, Lyra R, Lyra R, Naves LA. Acromegaly: clinical features at diagnosis. Pituitary. 2016;20(1):22–32.

    Article  Google Scholar 

  50. Chanson P, Salenave S. Acromegaly. Orphanet J Rare Dis. 2008;3(1):17.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Thorner M, Vance ML, Laws E, Horvath E, Kovacs K. The anterior pituitary. In:Williams Textbook of Endocrinology. 9th ed. Philadelphia: Elseiver; 1998. p. 295–306.

    Google Scholar 

  52. Vilar L, Fleseriu M, Bronstein MD. Challenges and pitfalls in the diagnosis of hyperprolactinemia. Arq. Bras. Endocrinol. Metabol. 2014;58(1):9–22.

    Article  PubMed  Google Scholar 

  53. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004;25(1):102–52.

    Article  CAS  PubMed  Google Scholar 

  54. Capatina C, Wass JAH. 60 YEARS OF NEUROENDOCRINOLOGY: acromegaly. J Endocrinol. 2015;226(2):T141–T60.

    Article  CAS  PubMed  Google Scholar 

  55. Wolinski K, Czarnywojtek A, Ruchala M. Risk of thyroid nodular disease and thyroid cancer in patients with acromegaly – meta-analysis and systematic review. PLoS One. 2014;9(2):e88787.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  56. Barkan AL, Beitins IZ, Kelch RP. Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion*. J Clin Endocrinol Metabol. 1988;67(1):69–73.

    Article  CAS  Google Scholar 

  57. Barkan AL, Stred SE, Reno K, Markovs M, Hopwood NJ, Kelch RP, et al. Increased growth hormone pulse frequency in acromegaly*. J Clin Endocrinol Metabol. 1989;69(6):1225–33.

    Article  CAS  Google Scholar 

  58. Caregaro L, Favaro A, Santonastaso P, Alberino F, Di Pascoli L, Nardi M, et al. Insulin-like growth factor 1 (IGF-1), a nutritional marker in patients with eating disorders. Clin Nutr. 2001;20(3):251–7.

    Article  CAS  PubMed  Google Scholar 

  59. Clayton KL, Holly JMP, Carlsson LMS, Jones J, Cheetham TD, Taylor AM, et al. Loss of the normal relationships between growth hormone, growth hormone-binding protein and insulin-like growth factor-I in adolescents with insulin-dependent diabetes mellitus. Clin Endocrinol. 1994;41(4):517–24.

    Article  CAS  Google Scholar 

  60. Pokrajac A, Wark G, Ellis AR, Wear J, Wieringa GE, Trainer PJ. Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice. Clin Endocrinol. 2007;67(1):65–70.

    Article  CAS  Google Scholar 

  61. Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, et al. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metabol. 2010;95(7):3141–8.

    Article  CAS  Google Scholar 

  62. Melmed S, Casanueva FF, Klibanski A, Bronstein MD, Chanson P, Lamberts SW, et al. A consensus on the diagnosis and treatment of acromegaly complications. Pituitary. 2012;16(3):294–302.

    Article  PubMed Central  Google Scholar 

  63. Misra M, Cord J, Prabhakaran R, Miller KK, Klibanski A. Growth hormone suppression after an oral glucose load in children. J Clin Endocrinol Metabol. 2007;92(12):4623–9.

    Article  CAS  Google Scholar 

  64. Arafat AM, Mohlig M, Weickert MO, Perschel FH, Purschwitz J, Spranger J, et al. Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index. J Clin Endocrinol Metab. 2008;93(4):1254–62.

    Article  CAS  PubMed  Google Scholar 

  65. Famini P, Maya MM, Melmed S. Pituitary magnetic resonance imaging for sellar and parasellar masses: ten-year experience in 2598 patients. J Clin Endocrinol Metabol. 2011;96(6):1633–41.

    Article  CAS  Google Scholar 

  66. Jane JA, Starke RM, Elzoghby MA, Reames DL, Payne SC, Thorner MO, et al. Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome. J Clin Endocrinol Metabol. 2011;96(9):2732–40.

    Article  CAS  Google Scholar 

  67. Swearingen B. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metabol. 1998;83(10):3419–26.

    CAS  Google Scholar 

  68. Laws ER, Thapar K. Pituitary surgery. Endocrinol Metab Clin N Am. 1999;28(1):119–31.

    Article  Google Scholar 

  69. Katznelson L, Atkinson J, Cook D, Ezzat S, Hamrahian A, Miller K. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly-2011 update. Endocr Pract. 2011;17(Supplement 4):1–44.

    Article  PubMed  Google Scholar 

  70. Liu F, Li W, Yao Y, Li G, Yang Y, Dou W, et al. A case of McCune-Albright syndrome associated with pituitary GH adenoma: therapeutic process and autopsy. J Pediatr Endocrinol Metab. 2011;24(5–6):283–7.

    PubMed  Google Scholar 

  71. Tuvia S, Atsmon J, Teichman SL, Katz S, Salama P, Pelled D, et al. Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. J Clin Endocrinol Metabol. 2012;97(7):2362–9.

    Article  CAS  Google Scholar 

  72. Tajima T, Tsubaki J, Ishizu K, Jo W, Ishi N, Fujieda K. Case study of a 15-year-old boy with McCune-Albright syndrome combined with pituitary gigantism: effect of octreotide-long acting release (LAR) and cabergoline therapy. Endocr J. 2008;55(3):595–9.

    Article  PubMed  Google Scholar 

  73. Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev. 2002;23(5):623–46.

    Article  CAS  PubMed  Google Scholar 

  74. Katznelson L. Pegvisomant for the treatment of acromegaly—translation of clinical trials into clinical practice. Nat Clin Pract Endocrinol Metab. 2007;3(7):514–5.

    Article  CAS  PubMed  Google Scholar 

  75. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med. 2000;342(16):1171–7.

    Article  CAS  PubMed  Google Scholar 

  76. Main KM, Sehested A, Feldt-Rasmussen U. Pegvisomant treatment in a 4-year-old girl with neurofibromatosis type 1. Horm Res Paediatr. 2006;65(1):1–5.

    Article  CAS  Google Scholar 

  77. Rix M, Laurberg P, Hoejberg AS, Brock-Jacobsen B. Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl. Eur J Endocrinol. 2005;153(2):195–201.

    Article  CAS  PubMed  Google Scholar 

  78. Bergamaschi S, Ronchi CL, Giavoli C, Ferrante E, Verrua E, Ferrari DI, et al. Eight-year follow-up of a child with a GH/prolactin-secreting adenoma: efficacy of pegvisomant therapy. Horm Res Paediatr. 2010;73(1):74–9.

    Article  CAS  PubMed  Google Scholar 

  79. van der Lely AJ, Biller BMK, Brue T, Buchfelder M, Ghigo E, Gomez R, et al. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metabol. 2012;97(5):1589–97.

    Article  CAS  Google Scholar 

  80. Marazuela M, Paniagua AE, Gahete MD, Lucas T, Alvarez-Escolá C, Manzanares R, et al. Somatotroph tumor progression during pegvisomant therapy: a clinical and molecular study. J Clin Endocrinol Metabol. 2011;96(2):E251–E9.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health, Bethesda, MD, USA

    Angeliki Makri

  2. Division of Pediatric Endocrinology, University of California, San Francisco, San Francisco, CA, USA

    Maya Lodish

Authors
  1. Angeliki Makri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maya Lodish
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maya Lodish .

Editor information

Editors and Affiliations

  1. Division of Pediatric Endocrinology, New York University, New York, NY, USA

    Brenda Kohn

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Makri, A., Lodish, M. (2019). Gigantism and Acromegaly. In: Kohn, B. (eds) Pituitary Disorders of Childhood. Contemporary Endocrinology. Humana Press, Cham. https://doi.org/10.1007/978-3-030-11339-1_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-11339-1_7

  • Published:

  • Publisher Name: Humana Press, Cham

  • Print ISBN: 978-3-030-11338-4

  • Online ISBN: 978-3-030-11339-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation